What’s Ahead for UnitedHealth (UNH) as Stock Drops 44% YTD?

UnitedHealth Group (UNH) stock has plunged 44% year-to-date, primarily due to soaring Medicare Advantage costs, a surprise CEO departure, and intensifying Department of Justice investigations into alleged overbilling. Despite the significant decline, Wall Street sentiment is mixed, with some analysts, like Bernstein, maintaining a 'Top Pick' rating citing discounted valuation and long-term earnings potential, while others have lowered price targets. Investors are now focused on the upcoming Q2 earnings call on July 29, anticipating a roadmap for recovery and updated 2025 guidance from CEO Stephen Hemsley, as a full-year EPS outlook below $18 could trigger further selling.

Analysis

UnitedHealth Group's (UNH) stock has experienced a severe 44% year-to-date decline, driven by a confluence of negative catalysts including escalating medical costs within its Medicare Advantage business, the abrupt resignation of its CEO in May, and a newly confirmed Department of Justice investigation into its billing practices. The selloff was initiated by a Q1 earnings miss and a full-year guidance reduction in April. Looking ahead to Q2 results on July 29, analysts project a 12.8% revenue increase to $111.50 billion, but a sharp drop in earnings per share to $4.48 from $6.80 a year prior, reflecting persistent margin compression. Despite these headwinds, Wall Street sentiment is divided; Bernstein has designated the stock a 'Top Pick,' citing a discounted valuation and forecasting a potential doubling of EPS by 2029, while firms like Wells Fargo and Truist have trimmed price targets due to weak sentiment and operational concerns. The upcoming earnings call is a pivotal event, with investors focused less on the Q2 numbers and more on the new CEO's strategic roadmap and, critically, the updated 2025 guidance, as an EPS forecast below $18 is seen as a key threshold that could trigger further selling.

Key Decisions for Investors

• Investors should closely monitor the July 29 earnings call for the new CEO's recovery plan and updated 2025 guidance, as a full-year EPS outlook below the $18 threshold could signal further downside risk.
• The current situation presents a high-risk, high-reward scenario; while the 'Moderate Buy' consensus and 24.11% average price target upside are notable, these must be weighed against the significant uncertainty from the ongoing DOJ investigation and persistent margin pressures.
• A cautious stance is warranted until there is greater clarity on the potential financial and reputational impact of the federal probe and tangible evidence that rising medical costs are being effectively managed.